c-Met: A Promising Therapeutic Target in Bladder Cancer

被引：13

作者：

Feng, Yanfei ^{[1
]}

Yang, Zitong ^{[2
]}

Xu, Xin ^{[2
,3
]}

机构：

[1] Zhejiang Chinese Med Univ, Affiliated Coll 2, Hangzhou, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, 79th Qingchun Rd, Hangzhou 310003, Peoples R China

来源：

CANCER MANAGEMENT AND RESEARCH | 2022年 / 14卷

基金：

中国国家自然科学基金;

关键词：

c; -Met; HGF; noncoding RNA; bladder cancer; review; HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; URINARY-BLADDER; SCATTER FACTOR; PROGNOSTIC INDICATOR; LUNG ADENOCARCINOMA; EXPRESSION; MIGRATION;

D O I：

10.2147/CMAR.S369175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.

引用

页码：2379 / 2388

页数：10

共 50 条

[1] HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers
Zhang, Hongli
Feng, Qingqing
Chen, Wei-Dong
Wang, Yan-Dong
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
[2] c-Met Signaling as a Therapeutic Target in Head and Neck Cancer
Centuori, Sara M.
Bauman, Julie E.
CANCER JOURNAL, 2022, 28 (05) : 346 - 353
[3] C-MET as a new therapeutic target for the development of novel anticancer drugs
Canadas, Israel
Rojo, Federico
Arumi-Uria, Montserrat
Rovira, Ana
Albanell, Joan
Arriola, Edurne
CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (04) : 253 - 260
[4] c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
Li, Chenwei
Wu, Jing-Jiang
Hynes, Mark
Dosch, Joseph
Sarkar, Bedabrata
Welling, Theodore H.
di Magliano, Marina Pasca
Simeone, Diane M.
GASTROENTEROLOGY, 2011, 141 (06) : 2218 - U395
[5] Androgen receptor in bladder cancer: A promising therapeutic target
Tripathi, Abhishek
Gupta, Shilpa
ASIAN JOURNAL OF UROLOGY, 2020, 7 (03) : 284 - 290
[6] Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
Gao, Jianjun
Inagaki, Yoshinori
Song, Peipei
Qu, Xianjun
Kokudo, Norihiro
Tang, Wei
PHARMACOLOGICAL RESEARCH, 2012, 65 (01) : 23 - 30
[7] MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met
Hu, Zhenghui
Lin, Yiwei
Chen, Hong
Mao, Yeqing
Wu, Jian
Zhu, Yi
Xu, Xin
Xu, Xianglai
Li, Shiqi
Zheng, Xiangyi
Xie, Liping
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 435 (01) : 82 - 87
[8] c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, JG
Burrows, J
Salgia, R
CANCER LETTERS, 2005, 225 (01) : 1 - 26
[9] c-Met Represents a Potential Therapeutic Target for Personalized Treatment in Hepatocellular Carcinoma
You, Hanning
Ding, Wei
Dang, Hien
Jiang, Yixing
Rountree, C. Bart
HEPATOLOGY, 2011, 54 (03) : 879 - 889
[10] The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
Varkaris, Andreas
Corn, Paul G.
Gaur, Sanchaika
Dayyani, Farshid
Logothetis, Christopher J.
Gallick, Gary E.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (12) : 1677 - 1684

← 1 2 3 4 5 →